These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3339228)

  • 41. Attenuated influenza A vaccine (Alice) in an adult population: vaccine-related illness, serum and nasal antibody production, and intrafamily transmission.
    Minor TE; Dick EC; Dick CR; Inhorn SL
    J Clin Microbiol; 1975 Nov; 2(5):403-9. PubMed ID: 1104655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel influenza A (H1N1) vaccine in various age groups.
    Zhu FC; Wang H; Fang HH; Yang JG; Lin XJ; Liang XF; Zhang XF; Pan HX; Meng FY; Hu YM; Liu WD; Li CG; Li W; Zhang X; Hu JM; Peng WB; Yang BP; Xi P; Wang HQ; Zheng JS
    N Engl J Med; 2009 Dec; 361(25):2414-23. PubMed ID: 19846844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.
    Black S; Nicolay U; Vesikari T; Knuf M; Del Giudice G; Della Cioppa G; Tsai T; Clemens R; Rappuoli R
    Pediatr Infect Dis J; 2011 Dec; 30(12):1081-5. PubMed ID: 21983214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-S™) in healthy Indian adult population.
    Kubavat AH; Mittal R; Patel PM; Jarsaniya DH; Pawar PR;
    J Postgrad Med; 2011; 57(2):102-8. PubMed ID: 21654130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months.
    Bernstein DI; Zahradnik JM; DeAngelis CJ; Cherry JD
    Pediatrics; 1982 Apr; 69(4):404-8. PubMed ID: 7070886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
    Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
    Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
    J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines.
    Brandriss MW; Betts RF; Mathur U; Douglas RG
    Am Rev Respir Dis; 1981 Dec; 124(6):681-4. PubMed ID: 7316272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Live, attenuated influenza A/England/42/72 (H3N2) virus vaccine: a field trial.
    Rubin RJ; Noble GR; Corey L; Brown WJ; Brandling-Bennett D; Kaye HS; Coleman MT; Gregg MB; Dowdle WR
    J Infect Dis; 1976 Jun; 133(6):613-20. PubMed ID: 778302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Safety and immunogenicity of split vaccines of influenza viruses].
    Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M; Press J; Varsano N; Levy V; Mendelson E; Sukenik S; Buskila D
    J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.